



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/395, C12N 15/00, C12P 21/08	A1	(11) International Publication Number: WO 00/15260 (43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/US99/21646 (22) International Filing Date: 16 September 1999 (16.09.99) (30) Priority Data: 60/100,639 16 September 1998 (16.09.98) US (71) Applicant: TANOX, INC. [-/US]; 10301 Stella Link, Houston, TX 77025 (US). (72) Inventors: LIOU, Ruey, S.; 3002 Arrowhead Drive, Sugar Land, TX 77479 (US). THOMAS, David; 7200 Almeda #624, Houston, TX 77054 (US). (74) Agent: MIRABEL, Eric, P.; Tanox, Inc., 10301 Stella Link, Houston, TX 77025 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ANTI-IGE GENE THERAPY (57) Abstract <p>Disclosed are gene constructs of anti-IgE antibodies or fragments thereof for therapy for allergic diseases. Upon introduction into suitable host, anti-IgE antibody gene constructs will direct the synthesis of an antibody (or its fragments) capable of binding to free IgE in serum but not binding to IgE bound to the high affinity receptor (FcεRI), or not binding to IgE bound to both the high affinity receptor and the low affinity receptor (FcεRII or CD23). The antibody (or fragments) which are synthesized may also inhibit IgE binding to the high affinity receptor or the low affinity receptor, or to both.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

ANTI-IGE GENE THERAPY**RELATED APPLICATION:**

This application claims priority to U.S. Provisional Application Serial No.
10 60/100,639 filed on September 16, 1998.

FIELD OF THE INVENTION

The invention relates to producing anti-IgE antibodies *in vivo* with gene therapy techniques.

BACKGROUND OF THE INVENTION:

15 IgE binds to the α chain of the high affinity IgE Fc receptor (Fc ϵ R1) present on mast cells and basophils, and to the low affinity receptor (Fc ϵ R2, CD23), present on monocytes/macrophages, lymphocytes and dendritic cells. Cross-linking of IgE molecules bound to mast cells by allergens aggregates the underlying Fc ϵ R1 receptors and triggers a series of biochemical events that result
20 in the activation of these cells and release of preformed and newly generated vasoactive and bronchoconstrictive substances, leading to the immediate hypersensitivity type responses such as the early phase of airway obstruction, allergic rhinitis, and other IgE-mediated allergic diseases. IgE cross-linking may also trigger the release of cytokines within the mast cells, including IL-4, IL-5, IL-
25 6, and TNF- α , suggesting an important role for IgE in the late phase of airway obstruction and the associated increase in bronchial hyperresponsive-ness. Moreover, by acting directly through Fc ϵ R2, IgE may also play a central role in the induction of a Th2-type response, and form part of a positive feedback loop leading to further increases in IgE and causing airway eosinophilia. Thus,

5 therapy that can interfere with IgE binding to high affinity receptors, or high and low-affinity receptors, should inhibit these biochemical events and reduce the early and late phase airway responses through blocking of mast cell degranulation.

Murine anti-IgE monoclonal antibodies which interfere in the binding to
10 both the high and low affinity receptors have been generated. These antibodies bind the high and low-affinity receptor-binding portions of human IgE located in the Cε3 domain. They bind to circulating IgE and IgE expressed on the surface B cells (membrane-bound IgE). They do not bind to IgE already bound to the FcεRI on mast cells and basophils or FcεRII on lymphocytes and other cells
15 bearing the receptor. Consequently, they do not activate these cells and trigger the release of mediators. Chimeric versions of the antibody, which consist of the heavy and light chain variable regions of the murine parent antibody and the heavy and light chain constant regions of the human γ1 and κ antibody isotypes, or a humanized version of the antibody which retains the complementarity
20 determining regions of the heavy and light chain variable regions with the majority of the remainder of the antibody (except for some portions of the framework regions) replaced with the heavy and light chain of the human γ1 and κ antibody isotypes, were shown to retain essentially identical antigen binding specificity and affinity. These antibodies have demonstrated their anticipated
25 activity in neutralizing circulating IgE and at the same time ameliorating allergic symptoms in atopic patients in human clinical studies.

The anticipated treatment regimen for anti-IgE antibodies is subcutaneous

5 injection at 3 - 4 weeks intervals during pollen season for allergic rhinitis, and
year round for allergic asthma. Gene therapy allows administering the gene
constructs for
the anti-IgE antibody or its fragments into appropriate tissue sites for a more
sustained expression of the antibody, resulting in better control of the serum IgE
10 levels.

SUMMARY OF THE INVENTION:

The invention includes gene constructs of anti-IgE antibodies or fragments
thereof for therapy. Upon introduction into suitable host, anti-IgE antibody gene
constructs will direct the synthesis of an antibody (or its fragments) capable of
15 binding to free IgE in serum but not binding to IgE bound to the high affinity
receptor (Fc ϵ RI), or not binding to IgE bound to both the high affinity receptor and
the low affinity receptor (Fc ϵ RII or CD23). The antibody (or fragments) which
are synthesized may also inhibit IgE binding to the high affinity receptor or the
low affinity receptor, or both.

20 These constructs include genes for whole antibody molecules as well as
modified or derived forms thereof, including immunoglobulin fragments like Fab,
single chain Fv (scFv) and F(ab')₂. The anti-IgE antibodies and fragments can be
animal-derived, human-mouse chimeric, humanized, Delimmunized™ or fully
from human. The gene construct can be introduced into a host with conventional
25 gene therapy techniques, including as naked DNA, DNA incorporated in
liposomes, DNA conjugated to lipids or to lipid derivatives or via suitable
plasmids or recombinant viral vectors.

5 In a preferred embodiment, humanized anti-IgE genes are incorporated in the genome of a recombinant adenovirus vector as an independent transcriptional unit, and packaged into infectious virus particles. Upon infection of host, the recombinant adenovirus virus will direct the production of either intact anti-IgE antibody or an scFv fragment in serum, which will bind free circulating
10 IgE, resulting in the reduction of free serum IgE. The binding of the antibody or fragment to IgE-bearing B cells may lower IgE levels by down-regulating IgE production by these B cells.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING:

SEQ ID NOS:1 to 21 are various primers, used in the manner described below.

15 SEQ ID NO:22 is the DNA sequence of the VH region of the humanized antibody Hu-901.

SEQ ID NO:23 is the amino acid sequence of the DNA of SEQ ID NO:22.

SEQ ID NO:24 is the DNA sequence of the V κ region of the humanized antibody Hu-901.

20 SEQ ID NO:25 is the amino acid sequence of the DNA sequence of SEQ ID NO:24.

SEQ ID NO:26 is the DNA sequence of the scFv fragment of the humanized antibody Hu-901.

25 SEQ ID NO:27 is the amino acid sequence of the DNA sequence of SEQ ID NO:26.

5 BRIEF DESCRIPTIONS OF THE DRAWINGS:

Figure 1 shows three schematic diagrams of the recombinant adenovirus constructs for the scFv fragment of Hu-901 (top), Hu-901 (middle), and Hu-901 with a murine constant region (lower). LITR refers to adenovirus type 5 (Ad5) 5' inverted terminal repeats along with the Ad5 origin of replication, the Ad5 encapsidation signal and the E1a enhancer; RITR refers to adenovirus type 5 (Ad5) 3' inverted terminal repeats; PhCMV is a promoter sequence derived from human cytomeglovirus; pA is a polyadenylation signal from SV40; E1 and E3 are the early region genes of adenovirus virus; GFP is the green fluorescence protein.

15 Figure 2 shows the expression of Hu-901(mC γ 2a, κ) in FVB mice infected with different doses of AdHu-901(mC γ 2a, κ) virus, where 1×10^9 pfu/mouse denotes each mouse infected with 1×10^9 plaque forming units of the recombinant adenovirus construct, and 5×10^8 pfu/mouse is a mouse infected with 5×10^8 plaque forming units of the recombinant adenovirus construct.

20 Figure 3 shows the expression of scFv_{Hu-901} in FVB mice infected with different doses of AdscFv_{Hu-901} virus.

Figure 4 shows the expression of scFv_{Hu-901} in FVB mice infected with the same dose of AdscFv_{Hu-901} virus.

Figures 5A to 5C show the effects of the expressed Hu-901(mC γ 2a, κ) and scFv
25 Hu-901 on the free circulating human C ϵ -containing IgE in Hu-IgE transgenic mice infected with AdHu-901(mC γ 2a, κ) and AdscFv_{Hu-901} viruses. Figure 5A depicts

5 the mean free circulating IgE from three untreated Hu-IgE transgenic mice; Figure 5B depicts the effect of Hu-901(mC γ 2a, κ) on free IgE levels in 5 mice infected with AdHu-901(mC γ 2a, κ) virus; and Figure 5C depicts the effect of scFv_{Hu-901} on free IgE levels in 5 mice infected with AdscFv_{Hu-901} virus.

MAKING AND USING THE INVENTION:

10 Producing the Antibody Gene Constructs of the Invention

The anti-IgE antibody gene constructs described herein preferably encode antibodies that target a specific epitope on IgE that overlaps with IgE binding epitopes to both high and low-affinity receptors, Fc ϵ RI and Fc ϵ RII, respectively. Exemplary anti-IgE antibody include the monoclonal antibodies produced by
15 hybridoma TES-C21, and its chimeric mouse-human form, produced by transfectoma lines TESC-2 (as described in International Application No. W092/17207). A humanized version of TES-C21 (designated Hu-901) is described in Australian Patent No. 675449. Gene constructs encoding Delimmunized™ and human antibodies with desired target specificity against IgE
20 can also be prepared using conventional techniques.

To prepare the gene constructs, the genes encoding the heavy and light chain of the chimeric antibody (Hu-901) is obtained through RT-PCR using the RNA from the transfectoma cell line producing the chimeric antibody. The cell line is deposited in the American Type Culture Collection (ATCC), 10801
25 University Blvd., Manassas, Virginia, 10110, under Accession No. BRL 10706. After sequence confirmation, the cDNA fragments are separately ligated to an expression vector under the transcriptional control of a strong promoter, for

5 example, human CMV promoter, the EF1 promoter or albumin promoter, and a polyadenylation signal site is provided either by the antibody DNA fragments or from the vector that contains the poly A site derived from SV40, β -globin gene or another appropriate source. Alternatively, the heavy and light chain genes can be placed in one plasmid construct either under separate promoter control or
10 under one promoter in a dicistronic arrangement. The antibody gene fragments can also be placed under the control of proper promoters that allow the turning on and off of gene expression with appropriate exogeneous factors, such as steroids or metal ions. Gene constructs for a humanized anti-IgE antibody can be similarly prepared using RNA from transfectoma cells producing a humanized
15 anti-IgE antibody. Examples include cell lines deposited in ATCC under the following Accession numbers: 11130, 11131, 11132, 11133. Alternatively, genomic DNA constructs containing exons, introns and immunoglobulin transcriptional regulatory sequences, promoters and enhancers can also be constructed. Gene constructs directing the expression of antibody fragments
20 such as Fab, F(ab')₂, single-chain Fv (scFv), can also be constructed by preparing the suitable gene segments encoding these antibody fragments which are ligated to suitably prepared vectors.

The gene constructs incorporated into the viral genome and subsequently packaged into suitable viral particles can allow a high efficiency gene delivery
25 through viral infection. Exemplary viral vectors commonly used for genetic therapy include retrovirus vectors, adenovirus vectors and adeno-associated virus (AAV) vectors. The more recently developed viral vectors suitable for

5 genetic therapy include lentivirus (HIV-1 or HIV-2 based vectors), and alphavirus
vectors (based on Sindbis virus and Semliki Forest virus). Anti-IgE gene
constructs can be incorporated into viral genomes of retroviruses, lentiviruses or
AAV vectors by subcloning of the transcriptional units into appropriate cassette
vectors containing necessary sequences for virus packing. Upon DNA
10 transfection of the resulting constructs into appropriate packaging cell lines that
produce viral components, the recombinant viral genomes can be properly
packaged into viable viral particles.

To incorporate the anti-IgE gene constructs into an adenoviral viral
genome, an additional step is generally taken. Since the adenoviral genome is
15 approximately 36 Kbp long, it is not convenient to directly insert the anti-IgE gene
into the genome through restriction endonuclease digestion and ligation.
Instead, anti-IgE genes are inserted in a cassette vector such as pAvCvSv
(Kobayashi K et al. (1996) *J. Biol. Chem.* 22:6852 - 60). The vector has a
pBR322 backbone and contains adenovirus type 5 (Ad5) 5' inverted terminal
20 repeats (ITR), the Ad5 origin of replication, the Ad5 encapsidation signal, the E1a
enhancer, multiple cloning sites, and Ad5 sequence from nucleotide positions
3328 to 6246, which serve as a homologous recombination fragment. The
resulting plasmid is then co-transfected into an appropriate host cell line, such as
293 cells (Graham FL, J Smiley, WC Russell and R Nairn, (1977) *J. Gen. Virol.*
25 36:59-72),, along with a DNA fragment containing the bulk of the adenoviral
genome with deletions in certain vital regions, such as the E1 and E3 genes.
Homologous recombination between two DNAs in overlapping regions would

5 allow the generation of a recombinant viral genome harboring the anti-IgE genes. This recombinant genome will be subsequently packaged into viable infectious viral particles in the 293 host cells. Incorporation of anti-IgE genes into the genome of alphaviruses or other viruses with a large genome can be similarly carried out to generate recombinant virus.

10 These gene constructs can be prepared as plasmids which can be delivered to host cells or tissues, either directly or as naked DNA, or as DNA incorporated in liposomes, conjugated with appropriate lipid components, or incorporated in viral vectors. They are preferably injected for administration. The gene constructs will be expected to direct the synthesis of anti-IgE or its
15 fragments, which will gradually enter the blood stream to interact with IgE. The recombinant virus constructs can be administered into an individual with allergic diseases via intra-muscular, intravenous, or subcutaneous routes. The dosage can be determined by extrapolating from animal experiments or determined in human clinical trials.

20 **Example 1. Preparation of DNA Construct for the Expression of a scFv Fragment of Anti-IgE with Humanized V Regions.**

A DNA construct for scFv without leader/signal peptide sequence for expression in mammalian cells was first prepared as follows. A polymerase
25 chain reaction (PCR) was set up by using the pHCMV- V_{H3} -huC₁ plasmid DNA as the template, and oligonucleotides H3-5 (5'-TCCCAGGTGCAGCTGGTGCAG-3' SEQ ID NO: 1) and H3-3 (5'-CTGAGCTCACGGTCACC-AG-3' SEQ ID NO: 2) as the 5' and 3' primers, respectively. A 380-bp DNA fragment of the Hu-901 heavy chain V gene, V_{H3} , was obtained. A 330-bp DNA fragment of the Hu-901 light

5 chain V gene, V_{L1} , was obtained by PCR using oligonucleotides L1-5 (5'-TCCGACATCCTGCTGACCCAG-3' SEQ ID NO: 3) and L1-3 (5'-GTTTGATCTCCACCTTGGT-3' SEQ ID NO: 4) as the 5' and 3' primers, respectively. The pHCMV- V_{L1} -huC κ plasmid DNA was used as the template in this PCR. The H3L1-LINK oligonucleotide (5'-CCCTGGTGACCGTGAG-
10 CTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCTGGGTGGCGGCGGATCTGACATCCTGCTGACCCAGAG-3' SEQ ID NO: 5) was synthesized to contain the 3' end of the V_{H3} exon, nucleotides encoding the GGGGSGGGGSGGGGS peptide (SEQ ID NO: 6), and the 5' end of the V_{L1} exon. PCR products of the V_{H3} and V_{L1} DNA fragments, together with the H3L1-LINK (SEQ ID NO: 5)
15 oligonucleotide were used in PCR under the condition of 94°C, 1min; 63°C, 4 min, for 7 cycles. A second PCR was carried out using the above mixture as the template and SFI-H3 (5'-GCGGCCAGCCGGCCAGGTGCAGCTGGTGCAGAG-3' SEQ ID NO: 7) and L1-NOT (5'-CTGCGGCCGCTTTGATCTCCACCTTGGTGCCCTG SEQ ID NO: 8)
20 as the primers under the conditions of 94°C, 1 min; 55°C, 2 min; 72°C, 2 min, for 30 cycles. The resulting 750-bp DNA fragments were digested with restriction enzymes *SfiI* and *NotI* and inserted into the pCANTAB5E phagemid vector. Sixteen out of 17 colonies were shown to contain the correct size inserts by PCR. One plasmid DNA was used as the template in PCR using 5TES (5'-
25 TCCCAAGCTTTCACCAT-GCAGGTGCAGCTGGTGCAGAG-3' SEQ ID NO: 9) and 3TES (5'-CCCGCTCGAGTCATTTGATCTCCACCTTGGTGC-3' SEQ ID NO: 10) as the primers. The 750-bp DNA fragments were digested with restriction

5 enzymes *Hind*III and *Xho*I and then inserted into the pcDNA3 plasmid to give pcDNA3-H3L1scFv.

A synthetic leader/signal peptide sequence was added to the leaderless scFv fragment according the process described below. A 240-bp DNA fragment containing the leader sequence and the 5' end of the humanized Hu-901 V region
10 gene (approximately to the end of FR2) was obtained by polymerase chain reaction (PCR) using oligonucleotide 5'TCCCAGATCTAAGCTTGCCGCCACCATGGACTGG3' (H3-5BH SEQ ID NO: 11) and 5'GCTGATCTCGCCCCACCACTCC3' (H3-3S SEQ ID NO: 12) as PCR primers and plasmid pHCMV-V_{H3hCγ1} as the template. This PCR product was
15 subsequently mixed with the leaderless scFv DNA fragment, and allowed for annealing and sequence extension in the presence of AmpliTaq under the conditions of 94°C, 1 min.; 55°C, 2 min.; and 72°C, 1 min., for 25 cycles. The resulting DNA was used directly as a template for the amplification of full-length signal/leader peptide-containing scFv fragment in a PCR reaction using
20 oligonucleotide H3-5BH (SEQ ID NO: 11) and 5'CCCGAGATCTCGAGTCATTTGATCTCCACC (L1-3BX SEQ ID NO: 13) as primers. The full-length scFv DNA thus obtained was ligated to vector pCR® Blunt (Invitrogen, Carlsbad, CA) according to the conditions recommended by the supplier and transformed to TOP10 One Shot™ competent cells. Six
25 transformants were randomly selected and the plasmids were purified for sequence confirmation. DNA sequence determination was performed with ABI Prism™ Big Dye™ Terminator Cycle Sequencing Reaction Kit and analyzed by

5 ABI Prism™ 300 Genetic Analyzer (Perkin Elmer, Foster City, CA). The plasmid DNA from one clone that contained the expected sequence encoding scFv was digested by *EcoRI*, treated with DNA polymerase Klenow fragment, and the scFv fragment was purified from agarose gel with a QIAquide Gel Extraction kit (QIAGEN, Valencia, CA) and ligated with *Bgl*II linker. After *Bgl* II digestion, the
10 scFv fragment was cloned into pAvCvSv vector (gift of Babie Teng, Institute of Molecular Medicine, University of Texas, Houston) through insertion at the *Bgl* II restriction site. The resulting plasmid, designated pAd-scFv_{Hu-901}, with the scFv fragment inserted at the correct orientation with respect to the hCMV promoter contained in the vector, was selected based on restriction mapping analysis
15 (Figure 1; first schematic shown).

Example 2. Preparation of DNA Construct for the Expression of Intact Anti-IgE with Humanized Variable Regions and Human Constant Regions.

20 DNA constructs for the expression of an intact humanized anti-IgE antibody was prepared as follows. Full length cDNA for the heavy and light chains of a humanized anti-IgE, Hu-901, was obtained by RT PCR. Total RNA was obtained from the Hu-901 cell line using TRIZOL reagent (Gibco) according to the manufacturer's instruction. 5 ml TRIZOL reagent was directly added into a
25 7.5 cm diameter culture dish to lyse the cells. The cell lysis step was followed by phase separation, RNA precipitation and RNA wash steps. One tenth of the recovered RNA was used to generate total polyA+ cDNA, from which Hu-901 cDNA was amplified with the SerperScript Preamplification System for First Strand cDNA synthesis (Gibco) according to the manufacturer's instruction. One

5 tenth of the synthesized total cDNA was used as a template to amplify Hu-901
cDNA with oligonucleotides 901VH5B, 5'
GGAGATCTCCACAGTCCCTGAACACAC, (SEQ ID NO: 14), 901CH3,
TCATTTACCCGGAGACAGGGA, (SEQ ID NO: 15) and 901CK3,
CTAACACTCTCCCCTGTTGAA (SEQ ID NO: 16). Expand High Fidelity PCR
10 system (Boehringer Mannheim) was used to decrease the mistake. The final
PCR product was cloned into the ZERO-BLUNT cloning vector and the
sequences was verified by DNA sequencing. Both heavy and light chains were
cloned into plasmid pAdTrack-CMV (Johns Hopkins University) with the
incorporation of the EF-1 α promoter for the light chain.

15 **Example 3. DNA Construct for the Expression of an Intact Anti-IgE
Antibody with Humanized Variable Regions and Murine
Constant Regions.**

The DNA fragment encoding the variable region of humanized anti-IgE, Hu-
20 901, heavy chain was obtained by PCR amplification using plasmid pHCMV-V_H-
HC γ 1 as the template and oligonucleotides H3-5BH (SEQ ID NO: 11) and H3-
3BL (5' TGAGCTCACGGTCACCAGGGT 3') (SEQ ID NO:21) as primers under
the reaction conditions of 94°C, 1 min.; 55°C, 2 min.; and 72°C, 1 min. for 25
cycles. The PCR product was treated with *Hind* III followed by Klenow fragment
25 and cloned into the Eco47 III and *Hind* III treated with pCDNA3/Vh_{MAM4.20}-mC γ 2a
plasmid and a subsequent removal of Vh_{MAM4.20} fragment. The resulting plasmid
with Hu-901 V_H gene inserted at the correct orientation, pCDNA3/ Vh₉₀₁-mC γ 2a,
was purified and analyzed by an ABI Prism™ 300 Genetic Analyzer to confirm
the Vh DNA sequence. The DNA fragment encoding Vh₉₀₁-mC γ 2a was then

5 obtained by *Hind* III and *Not* I double digestion of pCDNA3/ Vh₉₀₁-mC γ 2a, followed by Klenow treatment, and cloned into pAvCvSv vector digested with *Bgl* II, followed by treatments with Klenow and calf intestine alkaline phosphatase (CIAP). The resulting plasmid, designated pAdH901, contains Vh₉₀₁-mC γ 2a placed under the promoter control of hCMV provided by the pAvCvSv vector.

10 The DNA fragment encoding the variable region of humanized anti-IgE, Hu-901, light chain was obtained by PCR amplification using plasmid pHCMV-VL-HC κ as the template and oligonucleotides 5'TGAAGAAAGCTTGCCGCCACCATGGAG3' (L1-5H) (SEQ ID NO: 17) and 5'GCATCCGCTCGTTTGATCTCCACCTTGGT3' (L1-3B) (SEQ ID NO: 18) as
15 primers under the reaction conditions of 94°C, 1 min.; 55°C, 2 min.; and 72°C, 1 min., for 25 cycles. The DNA fragment encoding the constant region of murine C κ chain was obtained by PCR amplification using plasmid pCDNA3/Vh_{MAM4.20}-mC κ as the template and oligonucleotides MuK5-EBC: 5' CGGAATTCGAGCGGATGC-TGCACCAACTGTATCGATCT 3' (SEQ ID NO: 19);
20 Muk3-x, 5' GCTCTAGAGCTAAC-ACTCATTCCTGTTGAAGCTCTTGACA 3' (SEQ ID NO: 20) as primers under the reaction conditions of 94°C, 1 min.; 55°C, 2 min.; and 72°C, 1 min. for 25 cycles. The VL-901 PCR product was digested with *Bsr* BI, purified after agarose gel electrophoresis, then ligated to mC κ with prior treatment with *Bsr* BI and *Xba*I. The ligated DNA was then subjected to
25 PCR amplification using oligonucleotide primers L1-5H and Muk3-x (SEQ ID NO:20). The PCR product then was cloned into pCR® Blunt vector, and resulting plasmid pCR-VL₉₀₁-mC κ was analyzed by an ABI Prism™ 300 Genetic Analyzer

5 to confirm the DNA sequence.

To place the VL₉₀₁-mC_κ fragment under hCMV promoter control and eventually joined it with pAdH901(mC_γ2a) for the ultimate expression of the intact antibody, an intermediate holding vector was constructed. The DNA fragment containing hCMV promoter and enhancer sequences was obtained from pHCMV-
10 V_H-HC_γ2a by *Cla* I and *Hind* III digestion and cloned into pBluscript KS, previously digested with the same enzymes. The resulting plasmid was digested with *Bam* HI, treated with Klenow and CIAP, and used as the vector for the cloning of VL₉₀₁-mC_κ fragment, which was obtained by *Eco* RI and *Bam* HI digestion of PCR-VL₉₀₁mC_κ followed by Klenow treatment, to generate pKS-
15 hCMV-L₉₀₁. A DNA fragment containing SV40 polyadenylation site was obtained by *Hind* III and *Xba* I digestions of plasmid pREP8 followed by Klenow treatment and then cloned into pKS-hCMV-L₉₀₁(mC_κ) that was previously treated with *Cla* I, Klenow and CIAP, to generate pSpA-hCMV-L₉₀₁(mC_κ) .

To create the final plasmid construct for the expression of Hu-
20 901(mC_γ2a,κ), plasmid pSpA-hCMV-L₉₀₁(mC_κ) was digested with *Not* I, and the DNA fragment for SV40pA-hCMV-L₉₀₁(mC_κ) was purified from agarose gel and cloned into pAdH901(mC_γ2a), which was previously digested with *Cla* I, treated with Klenow, CIAP, ligated with *Not* I linker and subsequently digested with *Not* I. The resulting plasmid, pAdHu-901(mC_γ2a,κ), contained heavy and light chain
25 sequence of the humanized V/murine C antibody genes, each placed under independent hCMV promoter control and with its own polyadenylation signal downstream from the coding sequence.

5 **Example 4. Expression of Anti-IgE and Its scFv Fragment in Mammalian Cells via DNA Transfection.**

 The DNAs from plasmid pAd-scFv_{Hu-901} and pAdHu-901(mC γ 2a, κ) were purified with NucleoBond® plasmid purification column (Clontech Laboratories, Inc. Palo Alto, CA), and used to transfect 293 cells (human embryo kidney epithelial cells; transformed with adenovirus 5 DNA) via electroporation (Gene Pulser™, BioRad Laboratories, Inc. Richmond, CA) under the following conditions: cell density, 10⁷ cells/mL containing 10 μ g DNA in PBS, at 230 volts and 960 μ F. After 10 minutes incubation at room temperature, the cells were placed in 60-mm dish containing 5 mL of EMEM medium with 10% fetal calf serum and cultured at 37° C. The culture supernatants were collected 4 days post transfection and the level of scFv_{Hu-901} and Hu-901(mC γ 2a, κ) were measured by ELISA.

 The scFv_{Hu-901} expression was measured by a competitive ELISA in which the wells of Immulon II plate (Dynatech Laboratories, Chantilly, VA) were coated with goat anti-IgE (Jackson ImmunoResearch Laboratories, Inc., West Grove, Pennsylvania) at 1 μ g/mL for 16 hours at room temperature. The wells were then blocked with BLOTTO (5% not-fat milk in Phosphate buffered saline, 0.1 % Tween and 0.01% Thimerosal) at room temperature for 2 hours. After being washed with PBST (PBS with 0.1% Tween 20), wells were reacted with a murine V/human C ϵ chimeric IgE, SE44 (Sun LK *et al*, Transfectomas expressing both secreted and membrane-bound forms of chimeric IgE with anti-viral specificity, 1991, *J. Immunol.* 146:199), at 0.5 μ g/mL for one hour. Cultural supernatant was serially diluted at 1:2 and each dilution was mixed with equal volume of Hu-901-

5 HRP conjugate at 1:16,000 dilution. One hundred microliters of the mixtures were then added to the washed wells and incubated for one hour at room temperature. After being washed, peroxidase substrate solution containing 0.1% 3',3',5',5'-tetramethyl benzidine (Sigma Chemicals, St Louis Missouri) and 0.003% hydrogen peroxide (Sigma) was added at 200 μ l/well and incubated for
10 30 minutes at room temperature. The reaction was stopped by the addition of 50 μ l of 0.2 M sulfuric acid and the OD of the reaction mixture in each well was read with a BioTek ELISA reader (Winooski, VT). To determine the concentration of scFv_{Hu-901} produced by the transfected cells, purified Hu-901 was used to generate a standard curve. Using this assay, the cultural supernatant of 293
15 cells transfected with pAd-scFv_{Hu-901} was measured to contain approximately 4 μ g/mL of scFv_{Hu-901} 4 days post transfection.

The Hu-901(mC γ 2a, κ) expression was measured by an ELISA in which the wells of Immulon II plate were coated with an anti-idiotypic antibody against Hu-901 (mAb69-76-5, Tanox proprietary antibody) at 1 μ g/mL for 16 hours at room
20 temperature. After the wells were blocked for 2 hours at room temperature, cultural supernatants from cells transfected with pAd-Hu-901(mC γ 2a, κ) at 1:2 serial dilutions were added to the wells at 50 μ l/well and incubated for one hour at room temperature. After being washed, the wells were then added with 50 μ l/well of mAb69-76-5-HRP conjugate at 1:1000 dilution, and incubated at room
25 temperature for one hour. Afterwards, the wells were washed and peroxidase substrate solution was added at 100 μ l/well and incubated for 30 minutes at room temperature. The reaction was stopped by the addition of 50 μ l of 0.2 M sulfuric

5 acid and the OD of the reaction mixture in each well was read with a BioTek ELISA reader (Winooski, VT). To determine the concentration of Hu-901(mC γ 2a, κ) produced by the transfected cells, purified Hu-901 was used to generate a standard curve. Using this assay, the cultural supernatant of 293 cells transfected with pAd-Hu-901(mC γ 2a, κ) was measured to contain
10 approximately 100 ng/mL of Hu-901(mC γ 2a, κ) 4 days post transfection.

Example 5. Preparation of Recombinant Adenovirus Constructs for the Delivery of Anti-IgE Genes and Genes of Its scFv Fragment.

To change the mode of gene delivery into suitable hosts, plasmid constructs
15 pAd-Hu-901(mC γ 2a, κ) and pAd-scFv_{Hu-901} can be incorporated into adenovirus genome and packaged into infectious viral particles. This is achieved by the inverted terminal repeat sequences contained in the plasmids for the packaging and a short segment of adenoviral genome that allows homologous recombination with a near full length adenoviral DNA between the overlapping
20 regions. pAd-scFv_{Hu-901}, 10 μ g, was mixed with 2 μ g of plasmid pJM17 (McGrory WJ, DS Bautista and FL Graham (1988) *Virology* 163:614-617.), which contained the adenovirus genome with DNA insertion at the E1 region. The DNA mixture was then used to co-transfect 293 cells using calcium phosphate transfection system (Life Technologies, Gaithersburg, MD), in a 60-mm cultural dish. After
25 being exposed to DNA, the culture was incubated in IMEM medium containing 10 % FBS for overnight and then replaced with 5 ml tissue culture overlay agar (IMEM plus 1% SeaPlaque agarose). The second overlay was placed 4 - 5 days later. Adenovirus plaques appeared approximately 10 - 14 days post transfection. Isolated plaques were picked with long-stem pipette and the virus

5 particles were recovered by repeated freeze/thaw cycles. The virus was then used to infect 293 cells at 24-well plates, and the cultures were harvested when cytopathic effect of the virus infection was apparent (approximately 3 - 5 days). One hundred microliters of the virus suspension was heat inactivated, and 10 μ l of which from each plaque was subjected to PCR analysis using oligonucleotides

10 H3-5BH and L1-3B as primers to determine whether the virus contain scFV_{HU-901} gene. One isolated virus suspension that scored positive in this PCR analysis was further expanded by infection to 293 cells to generate crude virus lysate. To prepare highly purified virus stocks, 24 150-mm plates of 293 culture at approximately 80% confluence was infected with 80 μ l of crude virus lysate in 2

15 ml of infection media per plate (IMEM containing 2% FBS) for 90 minutes with rocking at 37° C. Afterwards, 20 ml of IMEM medium containing 10% FBS was added to each plate and the cultures were incubated at 37° C. Thirty-six to forty-eight hours post infection when cytopathic effects were apparent, culture supernatant was aspirated and the cells were scraped off the plate with rubber

20 policeman. Cell pellet were pooled and subjected with freeze/thaw cycles 4 times, and cell debris was removed by centrifugation at 10,000 x g. The cleared virus suspension was then loaded to CsCl step gradients containing CsCl at 1.25 g/ml (3 ml) and 1.40 g/ml (3 ml) in each of a 12-ml nitrocellulose ultracentrifuge tube, and subjected to ultracentrifugation at 35 K rpm in a Sorvall AH41 rotor.

25 The virus particles trapped in the interphase of the density gradient were collected, transferred to a second tube containing CsCl at 1.33 g/ml and centrifuged at 35 K for 24 hours. The double-banded virus particles were

5 collected from gradient, dialyzed against TMG buffer containing 10 mM Tris, pH 7.4, 1 mM MgCl₂, and 10% (v/v) glycerol with 3- 4 changes of buffer. The virus preparation thus obtained was distributed in small aliquots and stored at -70° C. The infectious titer of the virus stock was determined to be approximately 1 - 2 x10¹⁰ plaque forming unit per ml using standard titration method.

10 To generate the virus construct containing Hu-901(mCγ2a,κ) genes, an additional method was used. This method allows homologous recombination to occur in *E. coli* for Hu-901(mCγ2a,κ) genes to incorporated into viral genome as described . This was accomplished by transfer of the Hu-901(mCγ2a,κ) genes into pAd-Shuttle-CMV vector (He, T -C, S Zhou, LT da Costa, J Yu, KW Kinzler and B Vogelstein (1998) Proc. Natl. Acad. Sci. USA 95:2509-2514) by stepwise
15 insertion through the *Not* I site of the vector. The resulting plasmid, pAd-Shuttle-Hu-901(mCγ2a,κ) (Figure 1, third schematic shown), was then used along with pAdeasy-1 to cotransform *E. coli* BJ5183. Kanamycin-resistant transformants were analyzed by restriction analysis to identify clones undergone the
20 recombination, resulting in the incorporation of Hu-901(mCγ2a,κ) into viral genome. The plasmid DNA was purified, and used to transfect 293 cells via electroporation. Culture supernatant was collected 10 days post transfection, and shown to contain Hu-901(mCγ2a,κ) using the ELISA method described in Example 2. The cultural supernatant was then used to expand and preparation
25 for Ad-Hu-901(mCγ2a,κ) virus stock using procedures as described above. The virus stock thus obtained was determined to contain approximately 1 x 10¹⁰ pfu/mL. Figure 1 shows the schematic diagrams of the recombinant adenoviral

5 constructs.

Example 6. Expression of Anti-IgE and scFv in Recombinant Adenovirus Infected Cells.

Crude virus lysates of Ad-Hu-901(mC γ 2a, κ) and Ad-scFv_{Hu-901} viruses were
10 used to infect 293 cells at a multiplicity of infection of 1 in 100-mm cultural dish. Four days post infection, cultural supernatants were collected, cleared of cell debris, and assayed for the expression of Hu-901(mC γ 2a, κ) and scFv_{Hu-901} using ELISA procedures as ones described in Example 2, it was determined that the cultural supernatant contained 1 μ g/mL and 8 μ g/mL of Hu-901(mC γ 2a, κ) and
15 scFv_{Hu-901}, respectively. These assays also demonstrated the binding ability of the expressed protein, i.e., Hu-901(mC γ 2a, κ) to its anti-idiotypic antibody mAb 69-76-5, and scFv_{Hu-901} for its ability to compete with intact Hu-901 antibody in binding IgE. With slight modification of the assay format in which the goat anti-mouse IgG2a-HRP conjugate was used as the tracer antibody, it was also
20 demonstrated that the expressed intact antibody exhibited murine IgG2a isotype. The expressed scFv_{Hu-901} was further analyzed by Western blot analysis. Twenty microliters of supernatant from Ad-scFv_{Hu-901} viruses-infected cultural were resolved in 10% SDS-polyacrylamide gel under either reducing conditions, and the proteins were transblotted onto nitrocellulose membrane. The membrane
25 was then incubated in BLOTTO buffer for 1 hour at room temperature to block excess protein binding sites. It was subsequently reacted with mAb 69-76-5 at room temperature for overnight, followed by goat anti-mouse IgG Fc-HRP conjugate, at room temperature for one hour. In between the antibody incubations, the membrane was washed 3 times, 5 minutes each, with PBST.

5 After final wash, the membranes were reacted with one component TMB membrane peroxidase substrate solution (Kirkegaard & Perry Laboratory, Gaithersburg, MD). A protein band consistent with the size for a scFv protein was shown in a gel. The same gel showed the band pattern of affinity purified scFv_{Hu-901} for comparison.

10 **Example 7. Expression of Anti-IgE in FVB Mice Infected with Recombinant Adenovirus Constructs .**

Purified virus particles were used to infect two groups of FVB mice through tail vein. The amount of AdHu-901(mCγ2a,κ) virus were 5×10^8 and 1×10^9 pfu/mouse. Serum samples from treated animals were collected on day 1 prior to injection and on days 2, 4, 6, 8, 11, 16, 29, and 46 post injection. Expression of scFv was measured by an ELISA as described in Example 2. In that assay, mAb67-76-5 was immobilized onto wells of Immulon II plates to capture the expressed Hu-901(mCγ2a,κ), and the captured antibodies were detected by the mAb69-76-5-HRP conjugate followed by color development of the enzyme substrate. Purified Hu-901 served as standard for the quantitative assay. Results displayed in Figure 2 showed a dose-dependent expression of the active antibody, which peaked on days 2 - 4 post infection with the serum concentration reaching approximately 4.5 μg/mL and 2.5 μg/mL, for mice receiving 1×10^9 and 5×10^8 pfu/mouse of virus, respectively. For infection dose at 5×10^9 pfu/mouse, the side effects of the virus infection proved to be too toxic, and mice died within 4 days post infection. The serum levels of the expressed Hu-901(mCγ2a,κ) antibody quickly decreased to about 20 - 35% of peak level on day 11, and remained at approximately that level to day 46.

5 **Example 8. Expression of scFv in FVB Mice Infected with Recombinant Adenovirus Constructs.**

Purified virus particles were used to infect 6 FVB mice through tail vein. The amount of Ad scFv_{Hu901} virus ranged from 5×10^8 (2 mice), 1×10^9 (2 mice), 2.5×10^9 (1 mouse) and 5×10^9 (1 mouse) pfu/mouse. Serum samples from treated
10 animals were collected on day 1 prior to injection and on days 2, 4, 6, 8, 11, 15, 21, and 28, 35 and 58 post injection. Expression of scFv was measured by a competitive ELISA as described in Example 2. In that assay, wells of Immulon II plates were immobilized with goat-anti-IgE to capture a monoclonal IgE and the expressed scFv was quantified by the ability in competing with purified scFv
15 protein for binding to IgE.

Results shown in Figure 3 indicated a dose-dependent expression of scFv_{Hu901} in infected animals. At higher doses of infection tested (2.5×10^9 and 5×10^9 pfu/mouse), peak expression occurred on day 2 post infection, quickly decreased afterwards to essentially a residual level of expression beyond day 21 (less than
20 $40 \mu\text{g/mL}$). In the next dose tested (1×10^9 pfu/mouse), peak expression appeared to occur on day 6 or later and quickly decreased to residual expression. In the lowest dose tested (5×10^8 pfu/mouse), only low but appreciable levels of scFv expression was observed throughout the experiment. To examine the expressed scFv protein, $5 \mu\text{l}$ of serum from each infected animal
25 collected on day 2 were resolved in 10% SDS-PAGE, transblotted onto nitrocellulose membrane and reacted to mAb 69-76-5, followed by goat anti-mouse IgG (Fc)-HRP conjugate. The result of this immunoblot analysis indicated that the scFv expressed in the serum of animals infected with the lowest dose of

5 recombinant virus (5×10^8 pfu/mouse) was barely detectable (lanes 1 and 2), whereas in sera of animals infected with higher doses of virus, scFv expression was evident, giving bands consistent with molecular weight expected for scFv.

To test the variation of scFv expression in different mouse receiving the same dose of recombinant adenovirus, 5 FVB mice were infected with scFv_{Hu901} at 1.5×10^9 pfu/mouse. Serum samples from infected mice were collected on appropriate days post infection and measured for scFv expression by competitive ELISA described previously. Results shown in Figure 4 suggested that different host animal responded differently to the virus infection and exhibited different levels of scFv expression. Although it was unlikely, it could not be totally ruled out that these mice did not received equal amount of virus during injection. It is also worthy to note that in this experiment, all mice still exhibited significant levels of scFv expression on day 45 (100 μ g/mL), whereas in an earlier pilot experiment, 2 mice receiving presumably the same dose of virus showed lower level of scFv expression (50 μ g/mL, see Figure 2). This difference may reflect the difference in exact virus particles administered to the animals since they were from two different batches of preparation.

Example 9. Immune Response to the Expressed scFv.

Host response to the expressed transgene product, *i.e.*, anti-Hu-901(scFv) antibody response in the virus infected mice, was initially measured in an ELISA which detects the antibody reactivity to V regions of Hu-901. In this assay, wells of Immunlon II plates were coated with Hu-901 antibody. Serum samples of infected mice at 1:10 dilution were added to these wells and incubated for one

5 hour at room temperature. After non-reactive materials were washed off, the immune complex was detected by HRP-conjugated Hu-901, followed by color development of enzyme substrate.

Under these assay conditions the results indicate that only mice infected with low dose of virus (5×10^8 pfu/mouse) exhibited detectable levels of anti-scFv_{Hu-901} response, whereas anti-scFv_{Hu-901} response in mice infected with
10 higher doses of virus was not detectable even on day 58. However, while this assay can directly measure the anti-scFv_{Hu-901} or anti-Hu-901(mC γ 2a, κ) antibodies, it cannot detect these responses when the antibodies are complexed with excess of expressed scFv_{Hu-901} or Hu-901(mC γ 2a, κ) in serum.

15 To test whether animals infected with higher doses of AdscFv_{Hu-901}virus indeed induced immune responses, an alternative assay was used. In this assay, wells of Immulon II plates were immobilized with goat anti-human K antibody to catch the immune complexes through binding to scFv_{Hu-901} in serum samples. The complexes adsorbed onto the wells were then detected with HRP
20 conjugate of goat anti-mouse Fc antibody. Under these assay conditions all serum samples of AdscFv_{Hu-901}virus-infected mice were shown to have anti-antibody responses post day 8 of infection. However, because of the lack of appropriate immune complexes to serve as standard solutions, and also because sample dilution was needed for the assay, which tended to cause partial
25 dissociation of the complexes and obscured an accurate determination of the complexes, this assay did not allow a quantitative measurement of the level of the immune responses in these animals. This assay could not measure the

5 antibody responses in mice infected with AdHu-901(mC γ 2a, κ) virus, since the expressed Hu-901(mC γ 2a, κ) antibody contained murine constant regions and would bind to tracer antibodies in the assay even if it was bound to the wells devoid of anti-antibodies attached to it.

10 **Example 10. Generation of a Transgenic Mouse Line that Expresses an IgE Antibody Containing Human C ϵ Sequence.**

Chimeric Ig gene comprising human C ϵ region and the H chain V region of the murine Mab BAT123 (an anti-HIV antibody) was constructed. This chimeric gene was inserted into a pSV2gpt (L. K. Sun *et al.* *J. Immunol.* 146: 199-205, 15 1991) and the resulting plasmid was used as the ϵ transgene. Two hundred pg of the transgene plasmid DNA was microinjected into the nucleus of each egg from the FVB mice. A total of 128 fertilized eggs that survived pronuclear microinjections of the transgene were implanted in the oviduct of recipient female mice. From 23 offspring, three contained human C ϵ sequences. Genomic DNA 20 was prepared from a 1-cm segment from the tail. Copy numbers of the human ϵ transgene per haploid genome were determined by quantitative slot blots using the transgene plasmid DNA as the standards. Serum IgE levels were determined by ELISA using purified BAT123IgE as standards. The results are shown in Table 1. These three founder mice were used to establish transgenic 25 mouse lines. The properties of the F1, F2, and F3 mice are summarized in Tables 2 and 3. For experiments described below in Example 11, F2 or F3 transgenic mice expressing serum human IgE levels of 1 to 10 μ g/ml were used.

5 **Table 1. Characteristics of the founder transgenic mice.**

Mouse	Copy number of the ϵ transgene per haploid	Serum human IgE level ($\mu\text{g/ml}$)
21282	25	2.7
21288	25	5.8
21296	3	10.8

10 **Table 2. Transgenic F1 and F2 mouse lines.**

F0	F1			F2		
	Serum human IgE ¹		Transgene integration ^{2,3} (%)	Serum human IgE ¹		Transgene integration ^{2,3} (%)
	$\mu\text{g/ml}$	% positive		$\mu\text{g/ml}$	% positive	
21282	0.09-1.9	18/48 ⁴ (38)	+ 6/17(35)	0.01-6.8	33/42 (78)	++4/19 (21) +13/19 (68)
21288	0.04-1.6	12/32 (38)	+ 3/8(38)	0.05-4.1	28/41 (68)	++6/20 (30) +10/20 (50)
21296	0.02-5.9	18/33 (54)	+ 5/11(45)	0.01-3.7	24/31 (77)	++6/31 (19) +17/31 (55)

¹Serum levels of human IgE were determined by ELISA with a detection limit of 0.01 mg/ml.

²Transgene integration was determined by quantitative slot blots.

³+, heterozygotes; ++, homozygotes.

⁴ Number of positive mice/number of mice analyzed.

20 **Table 3. Transgenic F3 mouse lines.**

F0	F3		
	Serum human IgE ¹		Transgene integration ^{2,3} (%)
	$\mu\text{g/ml}$	% positive	
21282	0.02-3.5	11/11 ⁴ (100)	++ 11/11 (100)
21288	0.15-2.7	21/21 (100)	++ 17/17 (100)

¹Serum levels of human IgE were determined by ELISA with a detection limit of 0.01 mg/ml.

²Transgene integration was determined by quantitative slot blots.

³++, homozygotes.

⁴ Number of positive mice/number of mice analyzed.

5 **Example 11. Suppression of Human C ϵ -Containing IgE in Serum of Transgenic Mice Infected with Recombinant Adenovirus**

Heterozygous F1 progeny of the Hu-IgE transgenic mice, with circulating human C ϵ -containing IgE at a concentration in the range of 2 - 12 μ g/mL, were
10 used to test the ability of recombinant adenovirus constructs to suppress serum IgE. Two groups of mice, each consisting of 5 mice, were infected through tail vein injection of 1×10^9 infectious units of AdscFv_{Hu901} and Ad-Hu-901(mC γ 2a, κ), respectively. Serum samples from treated animals were collected several times prior to injection and on days 2, 4, 6, 9, 16, and 28 post injection. Free serum
15 human C ϵ -containing IgE in these samples was measured in an ELISA as follows. Wells of Immulon II plates were immobilized with mAb Hu-901 at 1.5 μ g/mL at room temperature for overnight. The wells were then blocked with BLOTTO at room temperature for 2 hours. After being washed with PBST, 50 μ l of serum samples diluted at 1:10 with BLOTTO were added to the wells and
20 incubated at room temperature for one hour. After the unbound materials were washed off, the wells were reacted with 50 μ l of mAb E-10-10-3 at 1.5 μ g/mL at room temperature for one hour. Mab E-10-10-3 is an anti-IgE which binds to IgE at an epitope not overlapping with Hu-901. After washing, wells were then incubated with 50 μ l of HRP conjugate of goat anti-mouse IgG Fc at 1:1000
25 dilution for one hour at room temperature. Finally, 100 μ l of the peroxidase substrate solution were added after wash and incubated at room temperature for 30 minutes. The enzyme reaction was terminated with the addition of 50 μ l of 0.2 M H₂SO₄, and the OD of the reaction mixture in each well was read at 450 nm.

5 The working range of the assay was between 2 and 64 ng/mL.

As shown in Figure 5A, serum IgE of untreated mice fluctuated significantly during the course of this experiment. Under no circumstances, however, did this fluctuation result in the reduction of circulating IgE to less than 1.5 μ g/mL. On the contrary, a sharp decrease in free serum IgE to a level between 20 - 200
10 ng/mL was noted in mice infected with AdscFv_{Hu901}(Figure 5B), representing greater than 96% of the suppression of free circulating IgE in these animals. This was apparently due to the suppression by the expressed scFv_{Hu901} in these mice, in which great majority, if not all, of IgE was bound by scFv_{Hu901}. This suppression of circulating IgE lasted over 6 days, and IgE levels started to
15 bounce back afterwards, coinciding with the decrease in the expression of scFv_{Hu901} in these mice. It has to be noted that the free IgE measured in this assay represented a slight over-estimation, since serum samples had to be diluted 10 fold, resulting in partial dissociation of the IgE-scFv_{Hu901} immune complex. It was also due to this dilution related dissociation, that free IgE levels in serum samples
20 collected beyond day 9 could not be accurately measured, since these samples required higher dilution in order to bring IgE levels to within the working range of the assay.

Ad-Hu-901(mC γ 2a, κ) was less effective in suppressing IgE in these transgenic mice. As noted in Figure 5C, infection of Ad-Hu-901(mC γ 2a, κ) only
25 resulted in a brief and less than complete suppression of IgE in these mice, achieving approximately 40 - 90% of IgE suppression only on day 4 post infection. This was perhaps due to a much lower level of expression of intact Hu-

5 901(mC γ 2a, κ) in the infected mice (Figure 2).

Overall, this experiment demonstrated that *in vivo* delivery of scFv_{Hu901} gene via a recombinant adenoviral vector could result in a high level expression of scFv_{Hu901}. The expressed scFv_{Hu901} subsequently bound circulating IgE, resulting in a drastic reduction of free IgE for a period of time. This approach
10 should provide an alternative approach to deliver anti-IgE or its antibody fragments for therapeutic application of IgE-mediated allergic diseases.

It should be understood that the foregoing description and examples are descriptive only and not limiting, and that the scope of the invention is limited only by the claims which follow, and includes all equivalents of the subject matter
15 of the claims.


5 **What is Claimed Is:**

1. A nucleic acid comprising portions encoding an anti-IgE antibody or a derivative or fragment thereof which does not bind to IgE bound to the high affinity IgE receptor.
2. The nucleic acid of claim 1 wherein the antibody or derivative or fragment
10 also does not bind to IgE bound to the low affinity IgE receptor.
3. The nucleic acid of claims 1 or 2 wherein the antibody or derivative or fragment inhibits binding to the high affinity receptor, the low affinity receptor, or to both of said receptors.
4. A nucleic acid encoding the anti-IgE antibody Hu-901.
- 15 5. A nucleic acid comprising a portion encoding the scFv fragment of the antibody Hu-901.
6. A recombinant expression vector comprising the nucleic acid of claims 1 or 2.
7. A recombinant expression vector comprising the nucleic acid of claim 3.
8. A recombinant expression vector comprising the nucleic acid of claims 4 or 5.
- 20 9. The nucleic acid of claim 6 wherein the vector is a plasmid or a viral vector.
10. The nucleic acid of claim 7 wherein the vector is a plasmid or a viral vector.
11. The nucleic acid of claim 8 wherein the vector is a plasmid or a viral vector.
12. The nucleic acid of claim 9 wherein the vector is an adenovirus vector.
13. The nucleic acid of claim 10 wherein the vector is an adenovirus vector.
- 25 14. The nucleic acid of claims 11 wherein the vector is an adenovirus vector.
15. A cell transformed with the nucleic acid of claims 1 or 2.
16. A cell transformed with the nucleic acid of claim 3.


- 5 17. A cell transformed with the nucleic acid of claims 4 or 5.
18. A mammal having cells transformed with the nucleic acid of claims 1 or 2.
19. A mammal having cells transformed with the nucleic acid of claim 3.
20. A mammal having cells transformed with the nucleic acid of claims 4 or 5.
21. A method of inducing a host cell to express an anti-IgE antibody or a
10 derivative or fragment thereof, comprising administering a formulation
including the nucleic acid of claims 1 or 2.
22. A method of inducing a host cell to express an anti-IgE antibody or a
derivative or fragment thereof, comprising administering a formulation
including the nucleic acid of claim 3.
- 15 23. A method of inducing a host cell to express the anti-IgE antibody Hu-901
comprising administering a formulation including the nucleic acid of claim 4.
24. A method of inducing a host cell to express the scFv fragment of the anti-IgE
antibody Hu-901 comprising administering a formulation including the nucleic
acid of claim 5.
- 20 25. A method of treating allergic diseases comprising administering a formulation
including the nucleic acid of claims 1 or 2.
26. A method of treating allergic diseases comprising administering a formulation
including the nucleic acid of claim 3.
27. A method of treating allergic diseases comprising administering a formulation
25 including the nucleic acid of claims 4 or 5.

FIG. 1


AdscFv_{Hu-901}



AdHu-901



AdHu-901(mCγ2a.κ)






FIG. 3




FIG. 4




FIG. 5A




FIG. 5B





FIG. 5C



SEQUENCE LISTING

<110> Ruey S. Liou

<120> ANTI-IGE GENE THERAPY

<130> 99-5

<150> 60/100,639

<151> 1998-09-16

<160> 27

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 21

<212> DNA

<213> primer

<400> 1

tcccaggtgc agctggtgca g

21

<210> 2

<211> 19

<212> DNA

<213> primer

<400> 2

ctgagctcac ggtcaccag

19

<210> 3

<211> 21

<212> DNA

<213> primer

<400> 3

tccgacatcc tgctgaccca g

21

<210> 4

<211> 19

<212> DNA

<213> primer

<400> 4

gtttgatctc caccttggt

19

<210> 5

<211> 85

<212> DNA

<213> primer

<400> 5

ccctggtgac cgtgagctca ggtggcggtg gctcgggcgg tggtagggtcg ggtggcggcg 60
gatctgacat cctgctgacc cagag 85

<210> 6

<211> 15

<212> DNA

<213> primer

<400> 6

ggggsggggs ggggs 15

<210> 7

<211> 35

<212> DNA

<213> primer

<400> 7

gcggcccagc cggcccaggt gcagctggtg cagag 35

<210> 8

<211> 34

<212> DNA

<213> primer

<400> 8

ctgcggccgc tttgatctcc accttggtgc cctg 34

<210> 9

<211> 38

<212> DNA

<213> primer

<400> 9

tcccaagctt tcaccatgca ggtgcagctg gtgcagag 38

<210> 10

<211> 33

<212> DNA

<213> primer

<400> 10

cccgtcgag tcatttgatc tccaccttgg tgc 33

<210> 11

<211> 34

<212> DNA

<213> primer

<400> 11

tcccagatct aagcttgccg ccaccatgga ctgg 34

<210> 12
<211> 22
<212> DNA
<213> primer

<400> 12
gctgatctcg cccacccact cc 22

<210> 13
<211> 30
<212> DNA
<213> primer

<400> 13
cccagatct cgagtcattt gatctccacc 30

<210> 14
<211> 27
<212> DNA
<213> primer

<400> 14
ggagatctcc acagtccttg aacacac 27

<210> 15
<211> 21
<212> DNA
<213> primer

<400> 15
tcatttacct ggagacaggg a 21

<210> 16
<211> 21
<212> DNA
<213> primer

<400> 16
ctaactctt cccctgttga a 21

<210> 17
<211> 27
<212> DNA
 <213> primer

<400> 17
tgaagaaagc ttgccgccac catggag 27

<210> 18
<211> 29

<212> DNA
 <213> primer

<400> 18
 gcacccgctc gtttgatctc caccttggt 29

<210> 19
 <211> 38
 <212> DNA
 <213> primer

<400> 19
 cggaattcga gcggatgctg caccaactgt atcgatct 38

<210> 20
 <211> 40
 <212> DNA
 <213> primer

<400> 20
 gctctagagc taacaactcat tcctgttgaa gctcttgaca 40

<210> 21
 <211> 21
 <212> DNA
 <213> primer

<400> 21
 tgagctcacg gtcaccaggg t 21

<210> 22
 <211> 369
 <212> DNA
 <213> human/murine

<220>
 <221> CDS
 <222> (1)...(366)

<400> 22
 cag gtg cag ctg gtg cag agc ggc gcc gag gtg aag aag ccc ggc gcc 48
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

agc gtg aag gtg agc tgc aag gcc agc ggc tac acc ttc agc atg tac 96
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Met Tyr
 20 25 30

tgg ctg gag tgg gtg agg cag gcc ccc ggc cac ggc ctg gag tgg gtg 144
 Trp Leu Glu Trp Val Arg Gln Ala Pro Gly His Gly Leu Glu Trp Val
 35 40 45

ggc gag atc agc ccc ggc acc ttc acc acc aac tac aac gag aag ttc 192
Gly Glu Ile Ser Pro Gly Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe
50 55 60

aag gcc agg gcc acc ttc acc gcc gac acc agc acc aac acc gcc tac 240
Lys Ala Arg Ala Thr Phe Thr Ala Asp Thr Ser Thr Asn Thr Ala Tyr
65 70 75 80

atg	gag	ctg	agc	agc	ctg	agg	agc	gag	gac	acc	gcc	gtg	tac	tac	tgc	288
Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
				85					90					95		

gcc agg ttc agc cac ttc agc ggc agc aac tac gac tac ttc gac tac 336
Ala Arg Phe Ser His Phe Ser Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr
100 105 110

tgg	ggc	cag	ggc	acc	ctg	gtg	acc	gtg	agc	tca		
Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser			369
		115					120					

```
<210> 23
<211> 122
<212> PRT
<213> human/murine
```

<400> 23															
Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
1				5					10				15		
Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Ser	Met	Tyr
			20				25						30		
Trp	Leu	Glu	Trp	Val	Arg	Gln	Ala	Pro	Gly	His	Gly	Leu	Glu	Trp	Val
		35					40					45			
Gly	Glu	Ile	Ser	Pro	Gly	Thr	Phe	Thr	Thr	Asn	Tyr	Asn	Glu	Lys	Phe
	50					55					60				
Lys	Ala	Arg	Ala	Thr	Phe	Thr	Ala	Asp	Thr	Ser	Thr	Asn	Thr	Ala	Tyr
65					70						75				80
Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85					90					95	
Ala	Arg	Phe	Ser	His	Phe	Ser	Gly	Ser	Asn	Tyr	Asp	Tyr	Phe	Asp	Tyr
			100					105					110		
Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser						
		115					120								

```
<210> 24
<211> 321
<212> DNA
<213> human/murine
```

```
<220>
<221> CDS
<222> (1) ... (321)
```

<400> 24

gac	atc	ctg	ctg	acc	cag	agc	ccc	ggc	acc	ctg	agc	ctg	agc	ccc	ggc	48
Asp	Ile	Leu	Leu	Thr	Gln	Ser	Pro	Gly	Thr	Leu	Ser	Leu	Ser	Pro	Gly	
1				5				10						15		

gag	agg	gcc	acc	ctg	agc	tgc	agg	gcc	agc	cag	agc	atc	ggc	acc	aac	96
Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Ser	Ile	Gly	Thr	Asn	
		20						25					30			

atc	cac	tgg	tac	cag	cag	aag	ccc	ggc	cag	gcc	ccc	agg	ctg	ctg	atc	144
Ile	His	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	Ile	
		35					40					45				

aag	tac	gcc	agc	gag	agc	atc	agc	ggc	atc	ccc	agc	agg	ttc	agc	ggc	192
Lys	Tyr	Ala	Ser	Glu	Ser	Ile	Ser	Gly	Ile	Pro	Ser	Arg	Phe	Ser	Gly	
	50					55					60					

agc	ggc	agc	ggc	acc	gac	ttc	acc	ctg	acc	atc	agc	agg	ctg	gag	ccc	240
Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Arg	Leu	Glu	Pro	
65					70					75					80	

gag	gac	ttc	gcc	atg	tac	tac	tgc	cag	cag	agc	gac	agc	tgg	ccc	acc	288
Glu	Asp	Phe	Ala	Met	Tyr	Tyr	Cys	Gln	Gln	Ser	Asp	Ser	Trp	Pro	Thr	
				85					90					95		

acc	ttc	ggc	cag	ggc	acc	aag	gtg	gag	atc	aaa						321
Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys						
			100					105								

<210> 25

<211> 107

<212> PRT

<213> human/murine

<400> 25

Asp	Ile	Leu	Leu	Thr	Gln	Ser	Pro	Gly	Thr	Leu	Ser	Leu	Ser	Pro	Gly	
1				5				10						15		
Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Ser	Ile	Gly	Thr	Asn	
		20						25					30			
Ile	His	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	Ile	
		35					40					45				
Lys	Tyr	Ala	Ser	Glu	Ser	Ile	Ser	Gly	Ile	Pro	Ser	Arg	Phe	Ser	Gly	
	50					55				60						
Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Arg	Leu	Glu	Pro	
65					70					75					80	
Glu	Asp	Phe	Ala	Met	Tyr	Tyr	Cys	Gln	Gln	Ser	Asp	Ser	Trp	Pro	Thr	
				85					90					95		
Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys						
			100					105								

<210> 26
 <211> 735
 <212> DNA
 <213> human/murine

<220>
 <221> CDS
 <222> (1)...(735)

<400> 26
 cag gtg cag ctg gtg cag agc ggc gcc gag gtg aag aag ccc ggc gcc 48
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 agc gtg aag gtg agc tgc aag gcc agc ggc tac acc ttc agc atg tac 96
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Met Tyr
 20 25 30
 tgg ctg gag tgg gtg agg cag gcc ccc ggc cac ggc ctg gag tgg gtg 144
 Trp Leu Glu Trp Val Arg Gln Ala Pro Gly His Gly Leu Glu Trp Val
 35 40 45
 ggc gag atc agc ccc ggc acc ttc acc acc aac tac aac gag aag ttc 192
 Gly Glu Ile Ser Pro Gly Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe
 50 55 60
 aag gcc agg gcc acc ttc acc gcc gac acc agc acc aac acc gcc tac 240
 Lys Ala Arg Ala Thr Phe Thr Ala Asp Thr Ser Thr Asn Thr Ala Tyr
 65 70 75 80
 atg gag ctg agc agc ctg agg agc gag gac acc gcc gtg tac tac tgc 288
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 gcc agg ttc agc cac ttc agc ggc agc aac tac gac tac ttc gac tac 336
 Ala Arg Phe Ser His Phe Ser Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr
 100 105 110
 tgg ggc cag ggc acc ctg gtg acc gtg agc tca ggt ggc ggt ggc tcg 384
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
 115 120 125
 ggc ggt ggt ggg tcg ggt ggc ggc gga tct gac atc ctg ctg acc cag 432
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Leu Leu Thr Gln
 130 135 140
 agc ccc ggc acc ctg agc ctg agc ccc ggc gag agg gcc acc ctg agc 480
 Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser
 145 150 155 160
 tgc agg gcc agc cag agc atc ggc acc aac atc cac tgg tac cag cag 528
 Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn Ile His Trp Tyr Gln Gln

	165	170	175	
aag ccc ggc cag gcc ccc agg ctg ctg atc aag tac gcc agc gag agc				576
Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Lys Tyr Ala Ser Glu Ser	180	185	190	
atc agc ggc atc ccc agc agg ttc agc ggc agc ggc agc ggc acc gac				624
Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp	195	200	205	
ttc acc ctg acc atc agc agg ctg gag ccc gag gac ttc gcc atg tac				672
Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Met Tyr	210	215	220	
tac tgc cag cag agc gac agc tgg ccc acc acc ttc ggc cag ggc acc				720
Tyr Cys Gln Gln Ser Asp Ser Trp Pro Thr Thr Phe Gly Gln Gly Thr	225	230	235	240
aag gtg gag atc aaa				735
Lys Val Glu Ile Lys	245			

<210> 27

<211> 245

<212> PRT

<213> human/murine

<400> 27

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala	1	5	10	15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Met Tyr	20	25	30	
Trp Leu Glu Trp Val Arg Gln Ala Pro Gly His Gly Leu Glu Trp Val	35	40	45	
Gly Glu Ile Ser Pro Gly Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe	50	55	60	
Lys Ala Arg Ala Thr Phe Thr Ala Asp Thr Ser Thr Asn Thr Ala Tyr	65	70	75	80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys	85	90	95	
Ala Arg Phe Ser His Phe Ser Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr	100	105	110	
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser	115	120	125	
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Leu Leu Thr Gln	130	135	140	
Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser	145	150	155	160
Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn Ile His Trp Tyr Gln Gln	165	170	175	
Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Lys Tyr Ala Ser Glu Ser				

[illegible]

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/21646

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 39/395; C12N 15/00; C12P 21/08

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/141.1, 145.1; 435/69.1, 70.21, 326, 337, 320.1; 536/23.53; 800/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,656,273 A (AMIRI ET AL) 12 August 1997 (12.08.97), see entire document, especially column 3, lines 60-67, column 4, lines 1, 12-18, column 6, lines 23-36 and Abstract.	1-27
X	US 4,940,782 A (RUP ET AL) 10 July 1990 (10.07.90), see entire document, especially Abstract, column 4, lines 65-68 and column 5, lines 1-2.	1, 3

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

09 DECEMBER 1999

Date of mailing of the international search report

20 JAN 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

M. Laurence
MARIANNE DIBRINO

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/21646

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/141.1, 145.1; 435/69.1, 70.21, 326, 337, 320.1; 536/23.53; 800/2

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

STN (MEDLINE, EMBASE, BIOSIS, CAPLUS, USPATFUL)

search terms: anti-IgE, FcεRI, FcεRII, high affinity receptor, antibody, Hu-901, transgenic, nucleic acid, Liou, Ruey, Thomas, David